FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pyrazolopyridine derivatives of formula (I) 
, a based pharmaceutical composition, and using them for treating and/or preventing disorders or conditions related to nictonamide adenine dinucleotide phosphatoxidase (NADPH-oxidase), as well as to a method for preparing them and an intermediate of formula (VIII) 
. In general formula (I), G1 is specified in H; and optionally substituted heteroaryl-C1-C6-alkyl; G2 is specified in H; optionally substituted C1-C6-alkyl; optionally substituted C2-C6-alkenyl; optionally substituted C2-C6-alkinyl; optionally substituted aryl; optionally substituted C1-C6-alkylaryl; optionally substituted aryl-C1-C6-alkyl; optionally substituted heteroaryl; optionally substituted C1-C6-alkylheteroaryl; optionally substituted heteroaryl-C1-C6-alkyl; optionally substituted C2-C6-alkenylaryl; optionally substituted aryl-C2-C6-alkenyl; optionally substituted C2-C6-alkenylheteroaryl; optionally substituted heteroaryl-C2-C6-alkenyl; optionally substituted C3-C8-cycloalkyl; optionally substituted C3-C8-heterocycloalkyl; optionally substituted C1-C6-alkyl-C3-C8-cycloalkyl; optionally substituted C3-C8-cycloalkyl-C1-C6-alkyl; optionally substituted C1-C6-alkyl-C3-C8-heterocycloalkyl and optionally substituted C3-C8-heterocycloalkyl-C1-C6-alkyl; G3 is specified in H; optionally substituted amino; optionally substituted aminoalkyl; optionally substituted aminocarbonyl; optionally substituted alkoxy, optionally substituted alkoxy-C1-C6-alkyl; optionally substituted carbonyl; optionally substituted C1-C6-alkyl; optionally substituted C2-C6-alkenyl; optionally substituted C2-C6-alkinyl; optionally substituted aryl; optionally substituted aryl-C1-C6-alkyl; optionally substituted C1-C6-alkylaryl: optionally substituted heteroaryl; optionally substituted C1-C6-alkylheteroaryl; optionally substituted heteroaryl-C1-C6-alkyl; optionally substituted C2-C6-alkenylaryl; optionally substituted aryl-C2-C6-alkenyl; optionally substituted C2-C6-alkenylheteroaryl; optionally substituted heteroaryl-C2-C6-alkenyl; optionally substituted C3-C8-cycloalkyl; optionally substituted C3-C8-heterocycloalkyl; optionally substituted C1-C6-alkyl-C3-C8-cycloalkyl; optionally substituted C3-C8-cycloalkyl-C1-C6-alkyl; optionally substituted C1-C6-alkyl-C3-C8-hterocycloalkyl and optionally substituted C3-C8-heterocycloalkyl-C1-C6-alkyl; G4 is specified in -NR2-C(O)-R1 and -(CHR3)m-(CH2)n-R4, G5 represents H.
EFFECT: preparing the pharmaceutical composition for treating and/or preventing the disorders and conditions related to nictonamide adenine dinucleotide phosphatoxidase.
16 cl, 3 tbl, 87 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRAZOLE PYRIDINE DERIVATIVES AS NADPH-OXIDASE | 2009 |
|
RU2548022C2 |
| PYRAZOLOPYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | 2009 |
|
RU2532161C2 |
| PYRAZOLOPYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | 2009 |
|
RU2569303C2 |
| PYRAZOLINE DIONE DERIVATIVES AS NADPH-OXIDASE INHIBITORS | 2010 |
|
RU2569855C2 |
| USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | 2018 |
|
RU2780354C2 |
| NOVEL PHOSPHATE COMPOUNDS, SYNTHESIS METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | 2014 |
|
RU2617682C2 |
| NEW PHTHALAZINONE DERIVATIVES AS AURORA A KINASE INHIBITORS | 2005 |
|
RU2397166C2 |
| CARBOXAMIDE COMPOUNDS AND USE THEREOF AS CALPAIN INHIBITORS | 2010 |
|
RU2567392C2 |
| PHENOXYMETHYL DERIVATIVES | 2016 |
|
RU2746481C1 |
| NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | 2013 |
|
RU2660429C2 |
